跳至主要内容
临床试验/jRCTs061180062
jRCTs061180062已完成不适用

The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia (The efficacy of reduced form of coenzyme Q10 in the Treatment of dementia)

未提供0 个研究点目标入组 100 人开始时间: 2017年2月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
100
主要终点
Frequency of participants with change of ADAS-Jcog being less than zero

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized Controlled Trial
干预模型
Parallel Assignment
主要目的
Prevention Purpose
盲法
Double Blind

入排标准

年龄范围
50age old over 至 89age old under(—)
性别
All

入选标准

  • Diagnosis is one of five types of dementia.
  • Alzheimer disease, Vascular dementia, Dementia of Lewy Body, frontotemporal dementia, Mild Cognitive Impairment: (MCI)
  • Clinical Dementia Rating (CDR) is 0.5,1 or 2 (mild-moderate dementia).
  • Mini-Mental State Examination (MMSE) score is between 15 and
  • Treatment has been kept with four drugs, donepezil, galantamine, rivastigmine, memantine and some other drug.
  • Agreement with clinical trial is between 50 and 89 years old.
  • A declaration of consent shall be valid if drawn up as a document providing sufficient evidence.

排除标准

  • Metabolic encephalopathy (hypothyroidism, Vitamin B12 deficiency)
  • Post head trauma
  • Delirium due to any drugs
  • Alcohol abuse
  • Depression under medication
  • Mental disorder treated by antipsychotic drugs
  • Schizophrenia, mania, severe heart failure, and severe liver injury.
  • Chronic renal failure with creatinine clearance less than 20 ml/min.
  • Treated with malignancy
  • Investigator decides inappropriate for enrollment

结局指标

主要结局

Frequency of participants with change of ADAS-Jcog being less than zero

时间窗: 48 weeks

Frequency of participants with change of ADAS-Jcog being less than zero after dose of reduced Coenzyme Q10

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验